arrow
M

Matti Annala

tampere university
H指数:43
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer

前瞻性多中心研究:循环肿瘤DNA与肿瘤组织指导FGFR靶向治疗在转移性尿路上皮癌中的应用

2026-02-270
OAAI
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer

去势抵抗性前列腺癌中AR位点突变的谱系和临床分级

2025-10-270
OAAI
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
2024-02-2813
OAAI
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
2024-01-0411
PRE
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
2023-11-066
OA
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial

CALGB 90203 3期试验中新辅助治疗后前列腺癌的分子特征

2023-09-074
PRE
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
2023-09-0110
PRE
Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer
2023-06-020
PRE
Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy

卡介苗免疫疗法治疗的非肌层浸润性膀胱癌的反应和复发的体细胞特征

2022-12-0110
PRE
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
2022-10-1733
OAAI
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
2021-07-0146
OAAI
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
2021-01-08101
OAAI
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
2020-12-0161
PREAI